A Study of CTD402 in T-ALL/LBL Patients

The goal of the TENACITY-01 clinical trial is to learn if CTD402 UCART is safe and effective for relapsed/refractory T-ALL/LBL patients. Participants with relapsed/refractory T-ALL/LBL over the age of 12 will be eligible to participate. Participants will receive one infusion of CTD402 on Day 0 and will be evaluated for anti-tumor activity by an independent review committee based on the NCCN criteria for T-ALL and the Lugano 2014 criteria for T-LBL. Patients will be followed for up to 24 months in this study and will be required to enroll under a separate long term follow up protocol to be f

Trial Details

NCT ID
NCT07070219
Phase
PHASE1 / PHASE2
Sponsor
BIOHENG THERAPEUTICS US LLC
Status
RECRUITING
Cancer Type
Acute Lymphoblastic (ALL) Leukemia
Interventions
  • CTD402 CAR T Cell Injection
Locations (sample)
  • Palo Alto, California, United States|37.44188,-122.14302
  • Denver, Colorado, United States|39.73915,-104.9847
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Rochester, Minnesota, United States|44.02163,-92.4699
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Male or female, ≥ 12 years of age.
  • Participants with body weight ≥ 40 kilogram.
  • Relapsed or refractory T-ALL/LBL is defined as one of the following:
  • Relapsed or refractory disease after two or more lines of systemic therapy;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Acute Lymphoblastic (ALL) Leukemia Trials on Trialify →